The importance of monotherapy in pregnancy

Neurology

Volumn 60, Issue 11 SUPPL. 4, 2003, Pages

  Pennell, Page B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; FOLIC ACID; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PRIMIDONE; VALPROIC ACID;

CLEFT LIP PALATE; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; DRUG CHOICE; DRUG SAFETY; EPILEPSY; FETUS OUTCOME; HUMAN; INTRAUTERINE GROWTH RETARDATION; MICROCEPHALY; MONOTHERAPY; NEURAL TUBE DEFECT; POSTNATAL CARE; PRACTICE GUIDELINE; PREGNANCY; PRENATAL CARE; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UROGENITAL TRACT MALFORMATION;

EID: 0037665175     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.60.11_suppl_4.s31     Document Type: Review

References (81)

1. Yerby MS. Quality of life, epilepsy advances, and the evolving role of anticonvulsants in women with epilepsy. Neurology 2000;55:S21-31.
2. Holmes LB. The teratogenicity of anticonvulsant drugs: a progress report. J Med Genet 2002;39:245-247.
3. Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000;321: 674-675.
4. Dolk H, McElhatton P. Assessing epidemiological evidence for the teratogenic effects of anticonvulsant medications. J Med Genet 2002;39: 243-244.
5. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001;344:1132-1138.
6. Hvas C, Henriksen T, Ostergaard J, Dam M. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. Br J Obstet Gynaecol 2000;107:896-902.
7. Yerby M, Collins S. Teratogenicity of antiepileptic drugs. In: Engel J, Pedley T, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:1195-1203.
8. Gilmore J, Pennell PB, Stern BJ. Medication use during pregnancy for neurologic conditions. In: Evans R, ed. Neurologic clinics: iatrogenic disorders. Philadelphia: WB Saunders, 1998:189-206.
9. Arpino C, Brescianini S, Robert E, et al. Teratogenic effects of antiepileptic drugs: use of an international database on malformations and drug exposure (MADRE). Epilepsia 2000;41:1436-1443.
10. Morrell M. Guidelines for the care of women with epilepsy. Neurology 1998;51(suppl 5):S21-27.
11. Yerby M, Devinsky O. Epilepsy and pregnancy. In: Devinsky O, Feldmann E, Hainline B, eds. Advances in neurology: neurological complications of pregnancy. New York: Raven Press, 1994:45-63.
12. Zahn CA, Morrell MJ, Collins SD, et al. Management issues for women with epilepsy: a review of the literature. Neurology 1998;51:949-956.
13. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: management issues for women with epilepsy (summary statement). Neurology 1998;51:944-948.
14. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999;33:145-158.
15. Lindhout D, Omtzigt J, Cornel M. Spectrum of neural-tube defects in 34 infants perinatally exposed to antiepileptic drugs. Neurology 1992; 42(suppl 5):111-118.
16. Canger R, Battino D, Canerini M, et al. Malformations in offspring of women with epilepsy: a prospective study. Epilepsia 1999;40:1231-1236.
17. Holmes LB, Rosenberger PB, Harvey EA, et al. Intelligence and physical features of children of women with epilepsy. Teratology 2000;61: 196-202.
18. Olafsson E, Hallgrimsson JT, Hauser WA, et al. Pregnancies of women with epilepsy: a population-based study in Iceland. Epilepsia 1998;39: 887-892.
19. Samrén EB, van Duijn CM, Koch S, et al. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38:981-990.
20. Hernandez-Diaz S, Werler M, Walker A. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608-1614.
21. Yerby M, Cawthon M. Fetal death, malformations and infant mortality in infants of mothers with epilepsy. Epilepsia 1996;37(suppl 5):98. Abstract.
22. Schupf N, Ottman R. Reproduction among individuals with idiopathic/cryptogenic epilepsy: risk factors for spontaneous abortion. Epilepsia 1997;38:824-829.
23. Schupf N, Ottman R. Risk of epilepsy in offspring of affected women: association with maternal spontaneous abortion. Neurology 2001;57: 1642-1649.
24. Tanganelli P, Regesta G. Epilepsy, pregnancy, and major birth anomalies: an Italian prospective, controlled study. Neurology 1992;42(4 suppl 5):89-93.
25. Dean J, Hailey H, Moore S, et al. Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth. J Med Genet 2002;39:251-259.
26. Lindhout D, Meinardi H, Meijer J, Nau H. Antiepileptic drugs and teratogenesis in two consecutive cohorts: changes in prescription policy paralleled by changes in pattern of malformations. Neurology 1992; 42(suppl 5):94-110.
27. Kaneko S, Otani K, Fukushima Y, et al. Malformations in infants of mothers with epilepsy receiving antiepileptic drugs. Neurology 1992; 42(suppl 5):68-74.
28. Oguni M, Dansky L, Andermann E, et al. Improved pregnancy outcome in epileptic women in the last decade: relationship to maternal anticonvulsant therapy. Brain Dev 1992;14:371-380.
29. Kaneko S, Otani K, Fukushima Y, et al. Teratogenicity of antiepileptic drugs: analysis of possible risk factors. Epilepsia 1988;29:459-467.
30. Samrén EB, van Duijn CM, Christiaens GC, et al. Antiepileptic drug regimens and major congenital abnormalities in the offspring. Ann Neurol 1999;46:739-746.
31. Dravet C, Julian C, Legras C, et al. Epilepsy, antiepileptic drugs, and malformations in children of women with epilepsy: a French prospective cohort study. Neurology 1992;42(4 suppl 5):75-82.
32. Sabry M, Farag T. Hand anomalies in fetal-hydantoin syndrome: from nail/phalangeal hypoplasia to unilateral acheiria. Am J Med Genet 1996;62:410-412.
33. Lu M, Sammel M, Cleveland R, et al. Digit effects produced by prenatal exposure to antiepileptic drugs. Teratology 2000;61:277-283.
34. Holmes L. The North American AED Pregnancy Registry. Charlestown, MA: Harvard Medical School, 2003.
35. Vajda F, O'Brien T, Hitchcock A, et al. The Australian registry of anti-epileptic drugs in pregnancy: multivariate logistic regression analysis demonstrating an increased risk for valproate, with a dose dependent relationship. Epilepsia 2002;43(suppl 7):211. Abstract.
36. Holmes L, Wyszynski D, Mittendorf R. Evidence for an increased risk of birth defects in the offspring of women exposed to valproate: findings from the AED pregnancy registry. Am J Obstet Gynecol 2002;187:5137. Abstract.
37. Duncan S, Mercho S, Lopes-Cendes I, et al. Repeated neural tube defects and valproate monotherapy suggest a pharmacogenetic abnormality. Epilepsia 2001;42:750-753.
38. Rosa F. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991;324:674-677.
39. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961-968.
40. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002;16:9-17.
41. Lamotrigine pregnancy registry, interim report, 9/1/92-3/31/02. Research Triangle Park, NC: GlaxoSmithKline, 2002.
42. Montouris G. Safety of gabapentin treatment during pregnancy. Epilepsia 2002;43(suppl 7):234. Abstract.
43. Rabinowicz A, Meischenguiser R, Ferraro S, et al. Single-center 7-year experience of oxcarbazepine exposure during pregnancy. Epilepsia 2002;43(suppl 7):208-209.
44. Leavitt A, Yerby M, Robinson N, et al. Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology 1992;42(4 suppl 5):141-143.
45. Koch S, Titze K, Zimmerman R, et al. Long-term neuropsychological consequences of maternal epilepsy and anticonvulsant treatment during pregnancy for school-age children and adolescents. Epilepsia 1999; 40:1237-1243.
46. Reinisch J, Sanders S, Mortensen E, Rubin D. In utero exposure to phenobarbital and intelligence deficits in adult men. JAMA 1995;724: 1518-1525.
47. Vanoverloop D, Schnell R, Harvey E, Holmes L. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 1992;14:329-335.
48. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996;75: 517-520.
49. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:15-21.
50. Adab N, Tudor-Smith C, Vinten J, Winterbottom J. A systematic review of long term developmental outcomes in children exposed to antiepileptic drugs in utero. Epilepsia 2002;43(suppl 7):230-231.
51. Battino D, Kaneko S, Andermann E, et al. Intrauterine growth in the offspring of epileptic women: a prospective multicenter study. Epilepsy Res 1999;36:53-60.
52. Stumpf D, Frost M. Seizures, anticonvulsants, and pregnancy. Am J Dis Child 1978;132:746-748.
53. Minkoff H, Schaffer R, Delke I, Grunevaum A. Diagnosis of intracranial hemorrhage in utero after a maternal seizure. Obstet Gynecol 1985; 65(suppl):22S-24S.
54. Teramo K, Hiilesmaa V. Pregnancy and fetal complications in epileptic pregnancies: review of the literature. In: Janz D, Bossi L, Dam M, et al, eds. Epilepsy, pregnancy and the child. New York: Raven Press, 1982: 53-59.
55. Teramo K, Hiilesmaa V, Bardy A, et al. Fetal heart rate during a maternal grand mal epileptic seizure. J Perinat Med 1979;7:3-5.
56. Nei M, Daly S, Liporace J. A maternal complex partial seizure in labor can affect fetal heart rate. Neurology 1998;51:904-906.
57. Pearlman M, Tintinalli J, Lorenz R. Blunt trauma during pregnancy. N Engl J Med 1990;323:1609-1613.
58. Pennell P, Gleba J, Clements S. Antiepileptic drug monitoring during pregnancy in women with epilepsy. Epilepsia 2000;41(suppl 7):200. Abstract.
59. Ohman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate and during lactation. Epilepsia 2000;41:709-713.
60. Yerby M, Collins S. Pregnancy and the mother. In: Engel J, Pedley T, eds. Epilepsy: a comprehensive textbook. Philadelphia: Lippincott-Raven, 1997:2027-2035.
61. Yerby MS. The use of anticonvulsants during pregnancy. Semin Perinatol 2001;25:153-158.
62. Pennell P, Montgomery J, Clements S, Newport D. Lamotrigine clearance markedly increases during pregnancy. Epilepsia 2002;43(suppl 7):234. Abstract.
63. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002;59:251-255.
64. Sathanandar S, Blesi K, Tran T, Leppik I. Lamotrigine clearance increases markedly during pregnancy. Epilepsia 2000;41(suppl 7):246. Abstract.
65. Levy R, Yerby M. Effects of pregnancy on antiepileptic drug utilization. Epilepsia 1985;26(suppl 1):S52-57.
66. Dansky L, Rosenblatt D, Andermann E. Mechanisms of teratogenesis: folic acid and antiepileptic therapy. Neurology 1992;42:32-42.
67. Wegner C, Nau H. Alteration of embryonic folate metabolism by valproic acid during organogenesis: implications for mechanisms of teratogenesis. Neurology 1992;42(suppl 5):17-24.
68. Botto L, Moore C, Khoury M, Erickson J. Medical progress: neural-tube defects. N Engl J Med 1999;341:1509-1519.
69. MRC Vitamin Study Research Group. Prevention of neural-tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131-137.
70. Hall J, Solehdin F. Folic acid for the prevention of congential anomalies. Eur J Pediatr 1998;157:445-450.
71. Crawford P. CPD-Education and self-assessment: epilepsy and pregnancy. Seizure 2001;10:212-219.
72. Committee on Educational Bulletins of the American College of Obstetricians and Gynecologists. ACOG educational bulletin, Number 23, December 1996. Seizure disorders in pregnancy. Int J Gynaecol Obstet 1997;56:279-286.
73. Buehler BA, Rao V, Finnell RH. Biochemical and molecular teratology of fetal hydantoin syndrome. Pediatr Neurogenet 1994;12:741-748.
74. Pschirrer E, Monga M. Seizure disorders in pregnancy. Obstet Gynecol Clin North Am 2001;28:601-611.
75. Malone F, D'Alton M. Drugs in pregnancy: anticonvulsants. Semin Perinatol 1997;21:114-123.
76. Howe A, Oakes D, Woodman P, Webster W. Prothrombin and PIVKA-II levels in cord blood from newborn exposed to anticonvulsants during pregnancy. Epilepsia 1999;40:980-984.
77. Srinivasan G, Seeler RA, Tiruvury A, et al. Maternal anticonvulsant therapy and hemorrhagic disease of the newborn. Obstet Gynecol 1982; 59:250-252.
78. Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Increased incidence of neonatal vitamin K deficiency resulting from maternal anticonvulsant therapy. Am J Obstet Gynecol 1993;168:923-928.
79. Cornelissen M, Steegers-Theunissen R, Kollee L, et al. Supplementation of vitamin K in pregnant women receiving anticonvulsant therapy prevents neonatal vitamin K deficiency. Am J Obstet Gynecol 1993; 168(3 pt 1):884-888.
80. Nelson KB, Ellenber JH. Maternal seizure disorder, outcomes of pregnancy, and neurologic abnormalities in the children. Neurology 1982; 32:1247-1254.
81. Moore K. The developing human: clinically oriented embryology. 4th ed. Philadelphia: WB Saunders, 1988.